Gentian Diagnostics ASA

OB:GENT Stock Report

Market Cap: NOK 601.5m

Gentian Diagnostics Management

Management criteria checks 1/4

Gentian Diagnostics' CEO is Matti Heinonen, appointed in Oct 2024, has a tenure of 1.42 years. total yearly compensation is NOK4.96M, comprised of 24.1% salary and 75.9% bonuses, including company stock and options. directly owns 0.049% of the company’s shares, worth NOK292.50K. The average tenure of the management team and the board of directors is 2.4 years and 1.3 years respectively.

Key information

Matti Heinonen

Chief executive officer

NOK 5.0m

Total compensation

CEO salary percentage24.12%
CEO tenure1.4yrs
CEO ownership0.05%
Management average tenure2.4yrs
Board average tenure1.3yrs

Recent management updates

Recent updates

Gentian Diagnostics ASA Just Missed Earnings - But Analysts Have Updated Their Models

Feb 14
Gentian Diagnostics ASA Just Missed Earnings - But Analysts Have Updated Their Models

Gentian Diagnostics ASA's (OB:GENT) 34% Cheaper Price Remains In Tune With Earnings

Feb 13
Gentian Diagnostics ASA's (OB:GENT) 34% Cheaper Price Remains In Tune With Earnings

With A 34% Price Drop For Gentian Diagnostics ASA (OB:GENT) You'll Still Get What You Pay For

Feb 13
With A 34% Price Drop For Gentian Diagnostics ASA (OB:GENT) You'll Still Get What You Pay For

Gentian Diagnostics' (OB:GENT) Performance Raises Some Questions

Oct 31
Gentian Diagnostics' (OB:GENT) Performance Raises Some Questions

Market Participants Recognise Gentian Diagnostics ASA's (OB:GENT) Revenues Pushing Shares 27% Higher

May 09
Market Participants Recognise Gentian Diagnostics ASA's (OB:GENT) Revenues Pushing Shares 27% Higher

Why Gentian Diagnostics' (OB:GENT) Earnings Are Weaker Than They Seem

Feb 20
Why Gentian Diagnostics' (OB:GENT) Earnings Are Weaker Than They Seem
User avatar

Launching NT-proBNP Test And Expanding Partnerships Will Broaden Cardiology Portfolio

Strategic partnerships and continual global expansion enhance Gentian's market presence and drive revenue growth.

Gentian Diagnostics ASA's (OB:GENT) P/S Is Still On The Mark Following 25% Share Price Bounce

Feb 07
Gentian Diagnostics ASA's (OB:GENT) P/S Is Still On The Mark Following 25% Share Price Bounce

Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%

Jun 29
Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Feb 14
Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation

Oct 28
Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation

We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn

May 11
We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn

Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?

Mar 20
Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?

What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?

Feb 21
What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?

Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?

Jan 17
Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?

CEO Compensation Analysis

How has Matti Heinonen's remuneration changed compared to Gentian Diagnostics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

NOK 13m

Sep 30 2025n/an/a

NOK 43m

Jun 30 2025n/an/a

NOK 42m

Mar 31 2025n/an/a

NOK 49m

Dec 31 2024NOK 5mNOK 1m

NOK 45m

Compensation vs Market: Matti's total compensation ($USD516.30K) is above average for companies of similar size in the Norwegian market ($USD352.44K).

Compensation vs Earnings: Insufficient data to compare Matti's compensation with company performance.

CEO

Matti Heinonen

1.4yrs
Tenure
NOK 4,958,000
Compensation

Mr. Matti Heinonen is Chief Executive Officer of Gentian AS. Mr. Heinonen has M.S. in Biochemistry from Helsingin yliopisto. Mr. Matti Heinonen is Chief Executive Officer of Gentian Diagnostics ASA from Oc...

Leadership Team

NamePositionTenureCompensationOwnership
Matti Heinonen
Chief Executive Officer1.4yrsNOK 4.96m0.049%
NOK 292.5k
Njaal Kind
CFO & COOno dataNOK 3.35m0.19%
NOK 1.1m
Frank Frantzen
Chief Technology Officer1.6yrsNOK 1.82m0.15%
NOK 901.5k
Aleksandra Havelka
Chief Scientific Officer3.2yrsNOK 2.43m0.013%
NOK 78.0k
Markus Jaquemar
Chief Growth Officerno dataNOK 3.20mno data
Tom Nilsen
Head of Product Development4.2yrsno datano data
2.4yrs
Average Tenure

Experienced Management: GENT's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kari Krogstad
Independent Non-Executive Directorno datano datano data
Christian Åbyholm
Non-Executive Directorless than a yearno datano data
Kjersti Grimsrud
Non-Executive Independent Director2.8yrsno datano data
Runar Vatne
Non-Executive Directorless than a yearno datano data
Hilja Ibert
Independent Chairperson1.8yrsNOK 5.81mno data
1.3yrs
Average Tenure
62.5yo
Average Age

Experienced Board: GENT's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/08 11:12
End of Day Share Price 2026/03/06 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gentian Diagnostics ASA is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinssonDNB Carnegie
Geir HolomDNB Carnegie